polidocanol injectable foam, 0.5% — Competitive Intelligence Brief

polidocanol injectable foam, 0.5% (polidocanol injectable foam, 0.5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sclerosing agent. Area: Dermatology.

phase 3 sclerosing agent Dermatology Small molecule

Target snapshot

polidocanol injectable foam, 0.5% (polidocanol injectable foam, 0.5%) — Boston Scientific Corporation. Polidocanol works by causing endothelial damage and subsequent thrombosis in the targeted vein.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
polidocanol injectable foam, 0.5% TARGET	polidocanol injectable foam, 0.5%	Boston Scientific Corporation	phase 3	sclerosing agent
Asclera	POLIDOCANOL	Provensis	marketed	Sclerosing Agent [EPC]		2010-01-01
Polidocanol with Glucose	Polidocanol with Glucose	UPECLIN HC FM Botucatu Unesp	marketed	Sclerosing agent
Foam sclerotherapy	Foam sclerotherapy	Imperial College London	marketed	Sclerosing agent
Varithena®	Varithena®	Boston Scientific Corporation	marketed	Sclerosing agent	Vein endothelium (non-receptor mediated tissue damage)
sclerotherapy with aethoxysclerol foam	sclerotherapy with aethoxysclerol foam	Medical University of Vienna	marketed	Sclerosing agent
Ethyl alcohol	Ethyl alcohol	South Egypt Cancer Institute	marketed	Cytotoxic agent / Sclerosing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sclerosing agent class)

1. Boston Scientific Corporation · 2 drugs in this class